Related Experiment Video
Updated: Jun 28, 2025
10:16
Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
Published on: August 17, 2022
3.2K
Self-amplifying RNA COVID-19 vaccine
Christopher J Wayne1, Anna K Blakney1
1Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, BC, Canada.
Cell
|April 12, 2024
Summary
Japan approved ARCT-154, a self-amplifying RNA COVID-19 vaccine, in November 2023. Clinical trials demonstrated comparable safety and efficacy to BNT162b2 mRNA vaccine at a lower dose.
Area of Science:
- Vaccinology
- RNA Therapeutics
- Infectious Disease Control
Background:
- The COVID-19 pandemic necessitated rapid vaccine development.
- mRNA vaccines have shown significant efficacy but require specific storage conditions.
- Novel vaccine platforms are being explored to improve accessibility and efficacy.
Purpose of the Study:
- To report the regulatory approval of ARCT-154, a novel self-amplifying RNA vaccine for COVID-19.
- To compare the safety and efficacy profile of ARCT-154 with an existing mRNA vaccine.
Main Methods:
- Regulatory submission and review process by Japan's Ministry of Health, Labour and Welfare.
- Analysis of clinical trial data comparing ARCT-154 and BNT162b2 mRNA vaccine.
Main Results:
- ARCT-154 received regulatory approval in Japan in November 2023.
- Clinical trials indicated that ARCT-154 possesses comparable safety and efficacy to the BNT162b2 mRNA vaccine.
- A lower dosage of ARCT-154 achieved comparable outcomes to the BNT162b2 vaccine.
Conclusions:
- ARCT-154 represents a significant advancement in COVID-19 vaccine technology.
- The self-amplifying RNA platform offers a promising alternative for vaccine development.
- Regulatory approval signifies confidence in the safety and efficacy of this new vaccine candidate.
Related Concept Videos
02:28Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K